Search Results
Your search for it matches 15947 pages
Showing 15651 - 15700Large Retrospective Study Finds Association Between Marriage and Cancer Outcomes
New results from a large retrospective study of the National Cancer Institute’s SEER database, published in the Journal of Clinical Oncology, show that patients with cancer who were married at the time of diagnosis live markedly longer compared to unmarried patients. Researchers also found...
Abiraterone Acetate/Prednisone Combination Delays Decline in Quality of Life in Men With Metastatic Prostate Cancer
According to a study published in The Lancet Oncology, abiraterone acetate (Zytiga) taken in conjunction with prednisone significantly delays progression of pain and quality of life deterioration in men with metastatic castration-resistant prostate cancer. The study was led by Ethan Basch, MD,...
Myeloma Foundation Launches Open Access Gateways to Accelerate Drug Development
The Multiple Myeloma Research Foundation (MMRF) has announced two open access gateways, the MMRF Researcher Gateway, which will upload genomic data as it becomes available and make it accessible to all researchers, and the MMRF CoMMunity Gateway, which will aggregate subtypes of myeloma patients...
ASTRO: Younger Adults With a Limited Number of Brain Metastases Have Improved Overall Survival After Stereotactic Radiosurgery Alone
When treated with stereotactic radiosurgery that is not combined with whole-brain radiotherapy, adult brain cancer patients who were 50 years old and younger were found to have improved survival, according to research presented on Sunday, September 22, at the American Society for Radiation...
ASTRO: Proton Therapy Yields Encouraging Outcomes for Pediatric Brain Tumor Patients
When used to treat pediatric patients with intracranial malignant tumors, proton therapy may limit the toxicity of radiation therapy while preserving tumor control, according to research presented on Sunday, September 22, at the American Society for Radiation Oncology’s 55th Annual Meeting...
ASTRO: Long-Term Androgen Deprivation in Patients With Intermediate-Risk Prostate Cancer Does Not Improve Overall Survival
A secondary analysis of the historic RTOG 9202 prostate cancer trial examined results of men with intermediate-risk prostate cancer who had received long-term hormonal therapy after radiation therapy. Investigators concluded that there were no additional benefits when compared to short-term...
Childhood Cancer Survivors Who Received Nephrotoxic Therapy May Be at Greater Risk for Late Renal Problems
A large study assessing glomerular function in adult survivors of childhood cancers who were treated with certain chemotherapy drugs or kidney surgery found that they had worse kidney function, which did not recover over time, compared with adult survivors who were not given nephrotoxic therapy....
Antiviral Treatment Improves Recurrence-Free and Overall Survival in HBV-Related Hepatocellular Carcinoma
Patients with hepatitis B virus (HBV)-related hepatocellular carcinoma have poor postoperative prognosis. In a study reported in Journal of Clinical Oncology, Jianhua Yin, MD, of the Second Military Medical University in Shanghai, and colleagues assessed the effects of nucleotide/nucleoside analog...
NCCN: Practical Considerations in Selecting Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia
Although imatinib (Gleevec) is the initial therapy for chronic myeloid leukemia (CML), several second-generation tyrosine kinase inhibitors are now approved for the treatment of this disease. Michael Millenson, MD, of Fox Chase Cancer Center in Philadelphia, reviewed practical considerations in...
Researchers Uncover Root Cause of Multiple Myeloma Relapse
Researchers have discovered why multiple myeloma frequently recurs after an initially effective treatment that can keep the disease at bay for up to several years. The study, published in Cancer Cell, was a collaboration between researchers at Princess Margaret Hospital in Toronto, Mayo Clinic in...
Scientists Find Possible Antidote for Tamoxifen-Induced Mental Fog
Researchers from University of Rochester Medical Center have shown scientifically what many women report anecdotally: that tamoxifen is toxic to cells of the brain and central nervous system (CNS), producing mental fogginess similar to “chemo brain.” In the study, published in the...
Widespread Contraindicated Use of Bevacizumab in Elderly Patients
In a study reported in Journal of Clinical Oncology, Dawn L. Hershman, MD, MS, of Columbia University, and colleagues assessed the use of bevacizumab in older patients with metastatic breast, lung, or colon cancer. They found that bevacizumab (Avastin) was contraindicated in approximately one-third ...
Statement by ASCO President Clifford A. Hudis, MD, FACP, in Support of the Rally for Medical Research Hill Day
“With the unprecedented scientific opportunities now promising significant progress against cancer and other life-threatening diseases, it is a tragedy that we are even considering cuts to our nation's investment in biomedical research. Yet, such cuts are already happening because of the...
MicroRNA Molecule Found to Be a Potent Tumor Suppressor in Lung Cancer
New research shows that microRNA-486 (miR-486) is a potent tumor-suppressor molecule in lung cancer, and that it helps regulate the proliferation and migration of lung cancer cells, as well as the induction of apoptosis in those cells. Published in the Proceedings of the National Academy of...
Young Breast Cancer Patients May Overestimate Benefit of Contralateral Prophylactic Mastectomy
Young women with breast cancer may overestimate the risk that cancer will occur in their other healthy breast and decide to undergo contralateral prophylactic mastectomy, a survey conducted by Dana-Farber Cancer Institute investigators indicated. The survey also shows that many patients may opt for ...
PDK1 Gene Identified as New Target for Melanoma Treatment
According to new research at Sanford-Burnham Medical Research Institute a gene encoding the enzyme phosphoinositide-dependent kinase-1 (PDK1) plays an essential role in the development and progression of melanoma. The finding, published online in Oncogene, may offer insight toward a new approach to ...
New Medical Device Treats Urinary Symptoms Related to Benign Prostatic Hyperplasia
The U.S. Food and Drug Administration has authorized the marketing of the UroLift system, a permanent implant to relieve low or blocked urine flow in men age 50 and older with benign prostatic hyperplasia. As men age, the prostate can become enlarged, also known as benign prostatic hyperplasia....
AACR Issues 2013 Cancer Progress Report
The American Association for Cancer Research (AACR) released its Cancer Progress Report 2013 today. And while there is much to celebrate in the significant progress made in cancer research—which has led to more effective therapies for the more than 200 types of cancer and increased...
FDA Approves First Generic Capecitabine to Treat Colorectal and Breast Cancers
The U.S. Food and Drug Administration (FDA) has approved the first generic version of capecitabine (Xeloda), an oral chemotherapy agent used in the treatment of metastatic colorectal cancer and breast cancers. Teva Pharmaceuticals USA has gained FDA approval to market generic capecitabine in 150...
New Plasma Biomarker Identified for the Diagnosis of Lung Cancer
A new plasma biomarker, isocitrate dehydrogenase 1 (IDH1), has been shown to be more sensitive in detecting non–small cell lung cancer (NSCLC) than currently used biomarkers, including CEA, Cyfra21-1, and CA125, according to a study published in Clinical Cancer Research. The study by Jie He,...
Gene Expression–Based Biomarker Predicts Long-Term Risk of Breast Cancer Recurrence
A comparison of three methods of predicting the risk of recurrence in women treated for estrogen-receptor–positive breast cancer found that only the breast cancer index (BCI)—a biomarker based on the expression levels of seven tumor-specific genes—accurately identified patients...
Tivozanib Improves Progression-Free Survival but Not Overall Survival vs Sorafenib in Metastatic Renal Cell Carcinoma
Tivozanib is a selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR1), -2, and -3. In a phase III trial reported in Journal of Clinical Oncology by Robert J. Motzer, MD, of Memorial Sloan-Kettering Cancer Center (MSKCC) and colleagues, tivozanib was found to...
Models Estimate Probability of Cancer in Pulmonary Nodules Detected on First Screening CT
In a study reported in The New England Journal of Medicine, Annette McWilliams, MD, of Vancouver General Hospital, and colleagues analyzed data from subjects undergoing low-dose computed tomography (CT) screening for lung cancer to identify factors that might predict whether lung nodules found on...
ASCO Issues Statement on National Childhood Obesity Awareness Month
Today, as many as 23 million children and teens are obese or overweight, and it is estimated that more than one-third of U.S. adults (more than 72 million people) are obese, according to a statement released by ASCO to help raise awareness of National Childhood Obesity Awareness Month....
Versatile MicroRNAs Block Cancer Blood Supply, Suppress Metastasis
A family of microRNAs (miR-200) blocks cancer progression and metastasis by stifling a tumor’s ability to weave new blood vessels to support itself, researchers at The University of Texas MD Anderson Cancer Center reported in Nature Communications. Patients with lung, ovarian, kidney, or...
Breast Cancer Treatment in 10 Years: George Sledge, MD, Offers His Predictions
In a keynote lecture during the 2013 Breast Cancer Symposium breast cancer expert and ASCO Past President George Sledge, MD, offered five predictions for the future of the medical management of breast cancer. Dr. Sledge is now Chief of Oncology at Stanford University School of Medicine, Palo Alto,...
Pomalidomide Plus Low-Dose Dexamethasone Improves Survival vs High-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma
Pomalidomide (Pomalyst) alone has shown limited efficacy in relapsed multiple myeloma, but synergistic effects have been noted when it is combined with dexamethasone. In a phase III trial (MM-003) reported in The Lancet Oncology, Jesus San Miguel, MD, of Universidad de Salamanca, and colleagues...
FDA Grants Breakthrough Therapy Status to Entinostat for Advanced Breast Cancer
Syndax Pharmaceuticals Inc today announced that the U.S. Food and Drug Administration (FDA) has designated entinostat as a Breakthrough Therapy for the treatment of locally recurrent or metastatic estrogen receptor (ER)-positive breast cancer when added to exemestane in postmenopausal women whose...
Researchers Uncover Genetic Cause of Childhood Acute Lymphoblastic Leukemia
For the first time, a genetic link specific to risk of childhood leukemia has been identified, according to a team of researchers from Memorial Sloan-Kettering Cancer Center, St. Jude Children’s Research Hospital, University of Washington, and other institutions. The discovery was reported...
Majority of Breast Cancer Deaths Occur in Younger, Unscreened Women, Study Finds
A new analysis has found that most deaths from breast cancer occur in younger women who do not receive regular mammograms. Published early online in Cancer, the study indicates that regular screening before age 50 should be encouraged. The use of mammograms to prevent breast cancer deaths has been ...
Following Neoadjuvant Chemotherapy, Biomarkers Change in 41% of Breast Cancer Patients
After neoadjuvant chemotherapy, 41% of early breast cancer patients experienced a change in status for the estrogen receptor, progesterone receptor, or HER2 oncogene, researchers from The University of Texas MD Anderson Cancer Center reported at the 2013 Breast Cancer Symposium in San Francisco...
NCI Scientists Use NanoString Technology to Identify Targets for Melanoma Immunotherapy
Researchers from the National Cancer Institute (NCI) have identified seven targets that could potentially be used to develop new immunotherapies for patients with metastatic melanoma. Their findings could increase the number of patients eligible for adoptive immunotherapy. The study was reported in ...
Molecular Marker Predicts Patients Most Likely to Benefit Longest From EGFR Inhibitors
Scientists at Johns Hopkins have identified a molecular marker called Mig6 that appears to accurately predict longer survival—up to 2 years—among patients being treated with the EGFR inhibitors gefitinib (Iressa) and erlotinib (Tarceva). Results from the preliminary study were published ...
Survival Advantage Seen in Glioblastoma Patients Taking Valganciclovir
Valganciclovir (Valcyte), a drug used to treat cytomegalovirus (CMV) eye infections in people with HIV/AIDS, may lengthen survival in patients with glioblastoma, a Swedish study has found. The researchers evaluated 50 patients with glioblastoma who received valganciclovir as an add-on to standard...
FDA Approves Nab-Paclitaxel for Late-Stage Pancreatic Cancer
The U.S. Food and Drug Administration (FDA) today expanded the approved uses of paclitaxel protein-bound particles for injectable suspension, albumin-bound (nab-paclitaxel, Abraxane) to treat patients with late-stage pancreatic cancer. “Patients with pancreatic cancer are often diagnosed...
New Laser-Based Tool Could Dramatically Improve the Accuracy of Brain Tumor Surgery
A new laser-based technology may make brain tumor surgery much more accurate, allowing surgeons to tell cancer tissue from normal brain at the microscopic level while they are operating, and avoid leaving behind cells that could spawn a new tumor. In a new paper published in Science Translational...
MRI Around the Time of Surgery Does Not Reduce Recurrence Rates in Women With DCIS
A large retrospective study reported that adding magnetic resonance imaging (MRI) to mammography before or immediately after surgery was not associated with reduced local recurrence or contralateral breast cancer rates among women with ductal carcinoma in situ (DCIS) of the breast who were treated...
Most Women Have an Inaccurate Perception of Their Breast Cancer Risk, Study Reveals
A large-scale survey of women undergoing mammography screening on Long Island, New York, indicates that the majority (90.6%) either underestimate or overestimate their lifetime risk for developing breast cancer. Furthermore, 4 in 10 women surveyed reported they had never discussed their...
New Report Examines Trends in End-of-Life Care for Patients With Advanced Cancer
Although fewer Medicare patients with cancer died in the hospital in 2010 than in the years 2003–2007, aggressive treatment continues at the end of life, according to a new report from the Dartmouth Atlas Project. The findings also show that a significant number of patients were likely to...
New Ultrasensitive Screening Method Can Detect Colon Cancer in Its Early Stages
A new ultrasensitive screening method that detects genetic variations that initiate colon cancer and can help in the detection of the cancer in its early stages could be used for noninvasive colon cancer screening, according to a study by Bettina Scholtka, PhD, Assistant Professor in the Department ...
No Apparent Benefit of Adjuvant Gefitinib in Resected NSCLC in Prematurely Closed Trial
As reported in Journal of Clinical Oncology by Glenwood D. Goss, MD, of the Ottawa Hospital Cancer Center, and colleagues, the prematurely closed NCIC CTG BR19 study showed no apparent survival benefit of adjuvant gefitinib (Iressa) vs placebo in patients with completely resected non–small...
Germline Missense Mutations in BTNL2 Increase Susceptibility to Prostate Cancer
A team of researchers led by Janet Stanford, PhD, of Fred Hutchinson Cancer Research Center has discovered that mutations in the gene BTNL2, which encodes a protein involved in regulating T-cell proliferation and cytokine production—both of which impact immune function—increase the risk ...
First-Line Brivanib Not Noninferior to Sorafenib in Advanced Hepatocellular Carcinoma
The investigational drug brivanib is a dual inhibitor of VEGF and fibroblast growth factor signaling, both implicated in hepatocellular carcinoma. In a noninferiority trial (BRISK-FL) reported in Journal of Clinical Oncology, Philip J. Johnson, MD, of the Institute of Translational Medicine,...
Scripps Florida Investigators Detail Critical Role of NOTCH1 Gene in Many Lung Cancer Cases
Investigators from the Florida campus of The Scripps Research Institute have shown that NOTCH1, a well-known cancer-causing gene implicated in a number of malignancies, plays a far more critical role in non–small cell lung cancer (NSCLC) than previously thought. These findings establish the...
High-Tech Imaging Contributes to Overdiagnosis, Overtreatment of Low-Risk Thyroid Cancers
A study from the Mayo Clinic Center for the Science of Health Care Delivery finds that advances in imaging technologies, including ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI), are fueling an epidemic in the diagnosis and treatment of thyroid cancers that are unlikely...
Preclinical Study Finds Tumor Suppressor May Actually Fuel Aggressive Acute Myeloid Leukemia
A study published this week in the Journal of Clinical Investigation suggests that blocking the RUNX1 protein normally credited with suppressing leukemia may be a promising therapeutic strategy for acute myeloid leukemia. Transcription Factor RUNX1 Researchers from Cincinnati Children's Hospital...
African American Women Less Likely to Receive HPV Vaccine Than Whites, Study Finds
African American women are less likely to receive the vaccine for human papillomavirus (HPV), even with access to health care, according to a study by researchers at the University of Pittsburgh School of Medicine. The findings, published today in the Journal of Adolescent Health, suggest a need...
New Screening Strategy May Detect Ovarian Cancer at Early Stages
A new screening strategy for ovarian cancer appears to be highly specific for detecting the disease before it becomes lethal. The strategy was described in a study published early online this week in Cancer. A clinical trial is ongoing to verify the findings. Karen Lu, MD, of The University of...
Low Risk of Transformation to Melanoma for Biopsy-Diagnosed Mildly or Moderately Dysplastic Nevi, So Surgical Excision May Not Be Indicated
The risk of transformation to melanoma appears very low for biopsy-diagnosed mildly or moderately dysplastic nevi, and routine surgical excision of nevi with a positive biopsy margin may not be indicated. Patients with biopsy-diagnosed moderately-to-severely and severely atypical nevi, however,...
Cost-Effectiveness of MRI Screening for Women With Familial Risk of Breast Cancer in the Netherlands
Annual screening for breast cancer with magnetic resonance imaging (MRI) has been found to be cost-effective in women aged 30 to 60 years who are BRCA1 or BRCA2 carriers or who have a 50% chance of being a carrier, and such screening is recommended in these women by many authorities. It is unclear...
